Truist Financial Corp Buys 530 Shares of Enovis Co. (NYSE:ENOV)

Truist Financial Corp lifted its stake in Enovis Co. (NYSE:ENOV) by 1.9% during the fourth quarter, HoldingsChannel reports. The firm owned 27,824 shares of the company’s stock after purchasing an additional 530 shares during the period. Truist Financial Corp’s holdings in Enovis were worth $1,221,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Diamond Hill Capital Management Inc. grew its holdings in shares of Enovis by 7.8% in the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock worth $129,352,000 after purchasing an additional 218,660 shares during the last quarter. DAVENPORT & Co LLC grew its holdings in Enovis by 6.0% during the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock worth $121,181,000 after acquiring an additional 157,216 shares in the last quarter. Royce & Associates LP grew its holdings in Enovis by 16.8% during the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after acquiring an additional 346,317 shares in the last quarter. State Street Corp grew its holdings in Enovis by 4.3% during the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company’s stock worth $70,913,000 after acquiring an additional 68,190 shares in the last quarter. Finally, River Road Asset Management LLC bought a new position in Enovis during the 3rd quarter worth about $51,341,000. 98.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC dropped their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday.

Enovis Stock Up 1.4 %

Shares of Enovis stock opened at $38.67 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis Co. has a 1 year low of $37.60 and a 1 year high of $63.96. The firm’s 50-day moving average is $44.81 and its two-hundred day moving average is $44.29. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -17.66 and a beta of 1.94.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. As a group, research analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.